IP Library Granted Patent US 11,623,002
Granted Patent B2
US 11,623,002 · App. 16/072,699 · Granted Apr 11, 2023

ALK polypeptides and methods of use thereof

Inventors: Adrienne Li (Cambridge, MA); Jackson Eby (Arlington, MA); Peter C. Demuth (Medford, MA)
Assignee: Elicio Therapeutics, Inc.
A61K39/001162A61K31/4545A61K31/506A61K31/5377A61K31/675A61K38/45A61K47/10A61K47/543A61K47/6911A61P37/04C07K14/00C07K14/705C12N9/00C12N9/1205A61K38/00A61K2039/55555A61K2039/6031A61K2039/627C07K2319/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,623,002
App. No.
16/072,699
Granted
Apr 11, 2023
Kind
B2
Abstract

The invention features immunogenic compositions containing anaplastic lymphoma kinase (ALK) polypeptides and methods of use thereof. The immunogenic compositions and methods of the invention may be used to treat a disease associated with ALK in a subject, such as cancer (e.g., a solid tumor cancer or an ALK+ cancer).

Claims (10)

1. An amphiphilic conjugate comprising:

(a) an albumin-binding domain;

(b) an ALK polypeptide; and

(c) an optional linker,

wherein the ALK polypeptide is 9 to 40 amino acids in length, comprises at least 6 contiguous amino acids from a sequence of SEQ ID NO: 3, and does not comprise a sequence of any one of SEQ ID NOs: 67-70 and 140-145, and

wherein the ALK polypeptide is conjugated directly to the albumin-binding domain or is conjugated to the albumin-binding domain through the linker.

2. The amphiphilic conjugate of claim 1 , wherein the albumin-binding domain is a lipid.

3. The amphiphilic conjugate of claim 1 , wherein the linker is selected from the group consisting of polymers, a string of amino acids, nucleic acids, polysaccharides, or a combination thereof.

4. An immunogenic composition comprising an amphiphilic conjugate of claim 1 .

5. A pharmaceutical composition comprising a therapeutically effective amount of an immunogenic composition of claim 4 and one or more pharmaceutically acceptable carriers or excipients.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 1, 2021
From: LI, ADRIENNE; DEMUTH, PETER C.; EBY, JACKSON
To: ELICIO THERAPEUTICS, INC.
Reel/Frame 055795/0369 →
CHANGE OF NAME Recorded Mar 24, 2021
From: VEDANTRA PHARMACEUTICALS, INC.
To: ELICIO THERAPEUTICS, INC.
Reel/Frame 055701/0590 →
Continuity (2)
Provisional Application 62288972 · Jan 29, 2016
Related Publication 20200405834A1 · Dec 31, 2020
Cited By (1)
US 12,370,245